Immune cell therapy shows promise for hard-to-treat ovarian cancers
NCT ID NCT02948426
First seen Jan 10, 2026 · Last updated May 20, 2026 · Updated 18 times
Summary
This early-phase study tested a new treatment for women with ovarian, fallopian tube, or peritoneal cancer that returned or didn't respond to standard therapy. The approach involved taking a type of white blood cell (monocytes) from each participant, activating them with immune-boosting drugs, and infusing them back into the abdomen. The goal was to see if this combination could safely shrink tumors or slow cancer growth. The study was terminated early, but results help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.